ACE2: the major cell entry receptor for SARS-CoV-2

F Scialo, A Daniele, F Amato, L Pastore, MG Matera… - Lung, 2020 - Springer
Despite the unprecedented effort of the scientific community, the novel SARS-CoV-2 virus
has infected more than 46 million people worldwide, killing over one million two hundred …

Prevalence of chemosensory dysfunction in COVID-19 patients: a systematic review and meta-analysis reveals significant ethnic differences

CS von Bartheld, MM Hagen… - ACS chemical …, 2020 - ACS Publications
A significant proportion of people who test positive for COVID-19 have chemosensory
deficits. However, the reported prevalence of these deficits in smell and taste varies widely …

Just 2% of SARS-CoV-2− positive individuals carry 90% of the virus circulating in communities

Q Yang, TK Saldi, PK Gonzales… - Proceedings of the …, 2021 - National Acad Sciences
We analyze data from the fall 2020 pandemic response efforts at the University of Colorado
Boulder, where more than 72,500 saliva samples were tested for severe acute respiratory …

Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein

M Calcagnile, P Forgez, A Iannelli, C Bucci, M Alifano… - Biochimie, 2021 - Elsevier
There is increasing evidence that ACE2 gene polymorphism can modulate the interaction
between ACE2 and the SARS-CoV-2 spike protein affecting the viral entry into the host cell …

The impact of ACE and ACE2 gene polymorphisms in pulmonary diseases including COVID-19

I Gintoni, M Adamopoulou, C Yapijakis - in vivo, 2022 - iv.iiarjournals.org
Chronic and acute respiratory diseases pose a major problem for public health worldwide
due to the high morbidity and mortality rates, while treatment options remain mostly …

Genetic landscape of the ACE2 coronavirus receptor

Z Yang, E Macdonald-Dunlop, J Chen, R Zhai, T Li… - Circulation, 2022 - Am Heart Assoc
Background: SARS-CoV-2, the causal agent of COVID-19, enters human cells using the
ACE2 (angiotensin-converting enzyme 2) protein as a receptor. ACE2 is thus key to the …

[HTML][HTML] Artificial intelligence–aided precision medicine for COVID-19: strategic areas of research and development

E Santus, N Marino, D Cirillo, E Chersoni… - Journal of medical …, 2021 - jmir.org
Artificial intelligence (AI) technologies can play a key role in preventing, detecting, and
monitoring epidemics. In this paper, we provide an overview of the recently published …

Host polymorphisms and COVID-19 infection

JR Delanghe, MM Speeckaert - Advances in Clinical Chemistry, 2022 - Elsevier
Abstract Coronavirus disease (COVID-19) is an infectious disease caused by a newly
discovered coronavirus, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) …

Cardiovascular damage in COVID-19: therapeutic approaches targeting the renin-angiotensin-aldosterone system

J Lumpuy-Castillo, A Lorenzo-Almorós… - International Journal of …, 2020 - mdpi.com
Coronavirus disease 2019 (COVID-19) is usually more severe and associated with worst
outcomes in individuals with pre-existing cardiovascular pathologies, including hypertension …

[HTML][HTML] Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection

RK Goyal, J Majeed, R Tonk, M Dhobi… - Reviews in …, 2020 - imrpress.com
Angiotensin-converting enzyme 2 (ACE2), the host cell-binding site for SAR-CoV-2, poses
two-fold drug development problems. First, the role of ACE2 itself is still a matter of …